必要な CMO / CDMO を検索して見つける
貴社の医薬品開発および製造プロジェクトのための高度なスキルを持つパートナーを見つけてください。
市場: EMA (EU)
サービス: Logistics, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: ISO, EMA (EU GMP), World Health Organization (GMP / HACCP)
バッチサイズ: Large, Medium
使用: Human
BSL (生物学的安全性レベル): 1, 2
治療専門分野 (ATC): (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (G) Genito urinary system and sex hormones
カテゴリ / 製品: 生物製剤, FDF / 医薬品
市場: EMA (EU), FDA (USA)
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), EMA (EU GMP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
BSL (生物学的安全性レベル): 1, 2
カテゴリ / 製品: 生物製剤, サービス, FDF / 医薬品
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
バッチサイズ: Small
治療専門分野 (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: ヨーロッパ
コンプライアンス: DIGEMID, BRCGS, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, ECOVADIS, TGA (Australia GMP), TITCK (Turkish Health Authorities), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), SQF (Safe Quality Food), NSF
使用: Human, Veterinary
BSL (生物学的安全性レベル): 1
カテゴリ / 製品: 化学合成品, サービス
バッチサイズ: Small
治療専門分野 (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (B) Blood and blood forming organs, (A) Digestive tract and metabolism
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World
サービス: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging
地域: アジア太平洋
バッチサイズ: Large, Small, Medium
使用: Human
カテゴリ / 製品: オリゴヌクレオチド, 化学合成品, サービス
コンプライアンス: ANVISA (Brazil B-GMP), NMPA (China GMP)
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
規制物質: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), TGA (Australia GMP), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), French Service-Public (CIR), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP)
バッチサイズ: Large, Small, Medium
使用: Human
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
治療専門分野 (ATC): (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (N) Nervous system, (R) Respiratory system, (S) Sensory organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones
カテゴリ / 製品: FDF / 医薬品
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), Turkish Health Authorities, CDSCO (India), TGA (Australia)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP)
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品, サービス
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
バッチサイズ: Small, Medium
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
地域: ヨーロッパ
コンプライアンス: ISO, Halal Research Council, ECOVADIS
バッチサイズ: Large, Small, Medium
カテゴリ / 製品: 化学合成品, サービス, 粒子工学
サービス: Development services, Manufacturing services, Analytical / QC services
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), MHRA (UK), MFDS (South Korea), CDSCO (India), TGA (Australia)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), World Health Organization (GMP / HACCP)
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品, 生物製剤, サービス, 粒子工学
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services
バッチサイズ: Small, Medium
OEB (職業性暴露バンディング): 2 (PDE = 1,000 - 10,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), MFDS (South Korea), Turkish Health Authorities, CDSCO (India), TGA (Australia)
地域: ヨーロッパ
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品, 生物製剤, サービス, 粒子工学
サービス: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services
治療専門分野 (ATC): (C) Cardiovascular system, (D) Dermatologicals, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (R) Respiratory system, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism
OEB (職業性暴露バンディング): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
バッチサイズ: Small, Medium
Apeloa Pharmaceutical Co., Ltd.
Apeloa Pharmaceutical Co., Ltd
Apeloa CDMO は、API、中間体、RSM 向けに世界クラスの検出、開発、製造サービスを提供します。
OEB (職業性暴露バンディング): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)
市場: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia)
地域: アジア太平洋
コンプライアンス: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ECOVADIS, NMPA (China GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)
バッチサイズ: Large, Small, Medium
使用: Human, Veterinary
カテゴリ / 製品: 化学合成品
サービス: Development services, Manufacturing services, Analytical / QC services, Regulatory services, Packaging
コンプライアンス: ICH, ISO, World Health Organization (GMP / HACCP)
市場: EMA (EU)
地域: ヨーロッパ
使用: Human, Veterinary
サービス: Development services, Analytical / QC services
カテゴリ / 製品: サービス